Theoretical stack · Cognition & Sleep

Cognitive Aging & Neuroprotection Stack

Cerebrolysin + Cortexin + Pinealon + DIHEXA

Low–Moderate

Theoretical educational discussion

This page summarizes a peptide combination as discussed in the research and user communities. It does not constitute medical advice, dosing recommendations, or instructions for personal use. Combination-specific human RCT evidence is generally absent for these stacks; per-compound evidence does not transfer additively to combinations.

Decisions about peptide therapy require an appropriately licensed clinician. We do not sell peptides.

At a glance

A neuroprotection-focused combination drawing on porcine brain extracts (approved abroad), Khavinson short peptides, and an angiotensin IV-derived synaptogenesis peptide. Distinct from the intranasal Semax/Selank stack — this targets cortical and hippocampal biology directly.

Compounds in the stack

Each compound's role in the combination, with link to its full peptide page for the underlying research.

Cerebrolysin
Porcine brain extract approved in Russia, China, and parts of Europe for stroke, dementia, and TBI; the most-evidence-graded compound in the stack
Approved abroad · IV/IM
Cortexin
Bovine cortical peptide complex used in Russian cognitive and stroke-recovery medicine
Approved in Russia · IM
Pinealon
Khavinson tripeptide (Glu-Asp-Arg) positioned for cognitive and circadian function within the framework
Investigational · Oral
DIHEXA
Angiotensin IV-derived hexapeptide claimed to enhance hippocampal synaptogenesis through HGF/c-Met signaling — preclinical only
Investigational · Multiple routes researched

Mechanistic rationale

The cognitive-aging picture has multiple converging pathologies: synaptic loss, cerebrovascular dysfunction, neuroinflammation, neurotrophic factor decline, and neurogenic capacity reduction. Single-mechanism interventions (cholinesterase inhibitors, NMDA modulators, anti-amyloid antibodies) have produced limited clinical impact in dementia and aging cognitive-decline. The peptide-research community's response has been multi-modal cocktails targeting different mechanisms simultaneously.

This stack samples four mechanistically distinct compounds: Cerebrolysin (porcine brain peptide complex with broad neurotrophic-mimicking effects, approved abroad), Cortexin (bovine cortical peptide complex with similar approval status in Russia), Pinealon (Khavinson short peptide framed as a cortical-tissue bioregulator), and DIHEXA (angiotensin IV-derived synaptogenesis peptide with striking preclinical claims).

Human and emerging evidence

The peer-reviewed literature on this combination is summarized below across two tiers — controlled human research (the highest standard) and preclinical / animal-model evidence.

Reported user experiences

Potential benefits and risks

Potential benefits

  • Cerebrolysin brings genuine controlled-trial evidence in stroke and dementia (where approved)
  • Multi-mechanism approach across neurotrophic, cortical, hippocampal, and circadian biology
  • Peptide framework offers distinct mechanism from cholinergic and glutamatergic small-molecule approaches
  • Reasonable use-case for post-TBI and stroke-recovery contexts under appropriate medical care

Potential risks

  • DIHEXA HGF/c-Met pathway is also implicated in cancer biology — chronic activation safety is unknown
  • Cerebrolysin is not FDA-approved (only abroad); access in U.S. is limited
  • Khavinson framework evidence is concentrated in originating research lineage
  • Established dementia requires evidence-based clinical care, not stack experimentation
  • Combination-specific safety data does not exist

Open questions

  • Does combining different neurotrophic-mimicking and synaptogenesis-promoting compounds produce additive or competing effects?
  • What populations (subjective cognitive decline, post-TBI, MCI) actually benefit?
  • Is the optimal pattern episodic (e.g., post-event) or chronic?
  • How does this stack compare to evidence-based cognitive-aging interventions (exercise, blood-pressure control, sleep)?

The takeaway

The Cognitive Aging stack is structurally similar to the Senescence stack — interesting multi-mechanism framework anchored by one decently-evidenced compound (Cerebrolysin abroad), with the others ranging from low to preclinical evidence. For users with specific contexts (post-stroke, post-TBI, mild cognitive complaints in older age), some components may be reasonable adjuncts to evidence-based care; for users seeking general cognitive enhancement, the lifestyle-and-medical foundation produces more reliable cognitive returns than peptide stacks. Cerebrolysin alone, in jurisdictions where it's approved, is the most defensible single component.

References

  1. Heiss WD, et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial (CASTA). Stroke. 2012;43(3):630-636. https://pubmed.ncbi.nlm.nih.gov/22282885/
  2. Khavinson VK, Linkova NS. Peptide bioregulators: a new class of geroprotectors. Adv Gerontol. 2020;10:34-45. https://pubmed.ncbi.nlm.nih.gov/?term=khavinson+pinealon
  3. McCoy AT, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013;344(1):141-154. https://pubmed.ncbi.nlm.nih.gov/23097214/